Metraipolis › archive › dc_ba7391981e0c

Efficacy and safety of efgartigimod PH20 SC for Sjögren's disease-associated dryness: study protocol for an investigator-initiated, multicenter, phase 2,… — Europe PMC PMID:41551508

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41551508
DOI
10.3389/fmed.2025.1719757
License (as archived)
solo-consultazione
Archived
2026-11-07T02:41:37.486Z
SHA-256 of the archived text
265266d20c2f9a3ee8b33b97b901e3ee0af62ec3960037cc14e232143282550b
Stable URL of this page
https://metraipolis.com/documento/dc_ba7391981e0c

How to cite

Efficacy and safety of efgartigimod PH20 SC for Sjögren's disease-associated dryness: study protocol for an investigator-initiated, multicenter, phase 2,… — Europe PMC PMID:41551508 — Europe PMC (en), https://europepmc.org/article/MED/41551508 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ba7391981e0c (Metraipolis archive dc_ba7391981e0c, sha256 265266d20c2f9a3ee8b33b97b901e3ee0af62ec3960037cc14e232143282550b)
BibTeX
@misc{dcba7391981e0c,
  title = {Efficacy and safety of efgartigimod PH20 SC for Sjögren's disease-associated dryness: study protocol for an investigator-initiated, multicenter, phase 2,… — Europe PMC PMID:41551508},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41551508},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ba7391981e0c; sha256 265266d20c2f9a3ee8b33b97b901e3ee0af62ec3960037cc14e232143282550b},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41551508. Agents can read the archived copy with the MCP tool read_document.